Patents Issued in November 21, 2017
  • Patent number: 9821055
    Abstract: The present invention provides a new adjuvant for administering vaccines.
    Type: Grant
    Filed: November 7, 2015
    Date of Patent: November 21, 2017
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Harm HogenEsch, Yuan Yao
  • Patent number: 9821056
    Abstract: The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 21, 2017
    Assignee: Inventprise, LLC
    Inventor: Subhash V. Kapre
  • Patent number: 9821057
    Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 21, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Patent number: 9821059
    Abstract: The present invention relates to a composition for stabilizing TNF?-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing TNF?-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of TNF?-binding protein used for treating various diseases, for example, an anti-TNF-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using TNF?-binding protein, for example, an anti-TNF-alpha antibody.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 21, 2017
    Assignee: ALTEOGEN INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Jin Hwan Kim, Minsoo Byun, Ji Hyeon Yeon
  • Patent number: 9821060
    Abstract: A heat-sensitive system comprising at least one nanoparticle bound covalently to at least one thermolabile molecule comprising an azo —N?N— functional group —N?N— in turn bound covalently to at least one active molecule selected from a fluorophore molecule and a drug is disclosed. The system converts an electromagnetic radiation into thermal energy exposed to an alternating magnetic field. Uses of the system are also disclosed.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: November 21, 2017
    Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
    Inventors: Andreas Riedinger, Teresa Pellegrino, Pablo Guardia Giros, Alberto Curcio, Roberto Cingolani, Liberato Manna
  • Patent number: 9821061
    Abstract: One or more techniques and/or products are disclosed using a process for preparing metallic nanoparticles. Resulting nanoparticles may comprise a gold-silver-gold core-shell-shell nanoparticles. Such nanoparticles can be formed by forming a gold core, providing certain materials to form a silver shell, and providing certain materials to form a gold shell. The metallic nanoparticles may be used in molecular sensing, catalysis, photothermal therapy, and other biologically-relevant technologies.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 21, 2017
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Louis Hamilton Haber, Tony Eugene Karam, Holden Tyler Smith
  • Patent number: 9821062
    Abstract: Disclosed are a cyanine dye compound and a preparation method therefor, and a dual-function agent for photodynamic therapy and a preparation method therefor. The provided cyanine dye compound is connected to multiple markers, which improves the accuracy of combination of dye and tumor cells, effectively reduces the background value, and avoids excessive residues in the liver. The provided cyanine dye compound is conjugated with the photosensitizer at 2?? position, so that tumor highly absorbs the conjugates.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: November 21, 2017
    Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Ravindra K. Pandey, Nayan Patel, Manivannan Ethirajan, Hua Bai, Zhenliang Chen
  • Patent number: 9821063
    Abstract: Pharmaceutical compositions comprising an aminoglycosidic antibiotic and at least one zinc-chelating agent in a specified concentration, and methods of inhibiting bacterial colonization, biofilm formation and if treating bacterial infections utilizing the compositions are provided. Topical formulations suitable for wound care, and surface-applicable formulations suitable for medical, industrial and household disinfecting needs are also described.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 21, 2017
    Assignee: University of Cincinnati
    Inventors: Andrew B. Herr, Gary Young
  • Patent number: 9821064
    Abstract: Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilization.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: November 21, 2017
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: Tianxiao Sun, Philip M. Levesque, Alicja T. Brown, Cynthia K. Lee
  • Patent number: 9821065
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 21, 2017
    Assignee: GENENTECH, INC.
    Inventors: Yatin Gokarn, Isidro E. Zarraga, Jonathan Zarzar, Thomas Patapoff, Christine Wurth
  • Patent number: 9821066
    Abstract: An antiseptic solution including, a cationic antiseptic agent, a film forming polymer, an anionic tinting agent, and a solvent, wherein the cationic antiseptic agent, the film forming polymer and the anionic tinting agent each remain solubilized within the solution for greater than about 1 hour at 25° C. and 60% relative humidity. The antiseptic agent is preferably octenidine dihydrochloride or chlorhexadine gluconate. The film forming polymer is preferably an acrylate polymer. The solvent is preferably ethanol, isopropanol, and n-propanol. When a drape is adhered to a dried surgical film via the antiseptic solution, the force required to peel the drape from the surgical film is at least about 105 g/25 mm.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 21, 2017
    Assignee: Carefusion 2200, Inc.
    Inventors: Kenneth M. Dokken, Tenoch Benitez, James Bardwell
  • Patent number: 9821067
    Abstract: Lipopeptide compounds having a central peptide HHHHHKHHHKKKHKHKKK (SEQ ID NO:15) and a lipophilic group attached to each terminus of the peptide, and salts thereof. The lipopeptides are useful for forming pharmaceutical compositions for delivery of nucleic acid agents, such as siRNA and mdRNA agents, as well as in methods for treating the signs and symptoms of disease.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: November 21, 2017
    Assignee: Marina Biotech, Inc.
    Inventors: Roger C. Adami, Michael E. Houston, Jr., Rachel E. Johns
  • Patent number: 9821068
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 21, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Dennis Buckley, Georg Winter
  • Patent number: 9821070
    Abstract: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: November 21, 2017
    Assignee: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Oren Hershkovitz
  • Patent number: 9821071
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: November 21, 2017
    Assignees: Emory University, Georgia Tech Research Corporation, Georgia State University Research Foundation, Inc.
    Inventors: Niren Murthy, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • Patent number: 9821072
    Abstract: The present invention relates to activated neurotensin, pharmaceutical compositions comprising the same, and the uses thereof. The compounds and compositions of the invention may be used, e.g., to reduce body temperature, attenuate or halt seizures, reduce excitotoxicity, promote neuroprotection, reduce neuroinflammation and aberrant axonal sprouting or reduce pain.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: November 21, 2017
    Assignees: VECT-HORUS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Guillaume Jacquot, Pascaline Lecorche, Michel Khrestchatisky
  • Patent number: 9821073
    Abstract: Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an MHC-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes. The provided proteinaceous molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 21, 2017
    Assignee: APO-T B.V.
    Inventors: Maria Johanna J. E. Van Driel, Johan Renes
  • Patent number: 9821074
    Abstract: Conjugate compounds of formula (A): wherein: R2 is ?where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 21, 2017
    Assignees: Genentech, Inc., MedImmue Limited
    Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
  • Patent number: 9821075
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: November 21, 2017
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 9821076
    Abstract: The design and generation of a number of chimeric VSV-G (or VSV-G variants) proteins are used as transfer vehicles to enhance delivery of nucleic acids like plasmid DNA, single and double stranded DNA and RNA, and antisense oligonucleotides into human and animal cells. These chimeric VSV-G protein-nucleic acid transfer vehicles have widespread applications to deliver nucleic acids for exon skipping and gene delivery for gene replacement in human and animals.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 21, 2017
    Assignee: Serendipity Biotech Inc.
    Inventor: Sujata Acharjee
  • Patent number: 9821077
    Abstract: The present invention relates to the provision of nanoparticular formulations comprising a PEG-alkyl block copolymer and a near infrared fluorescent dye, the preparation of these nanoparticular formulations, pharmaceutical compositions comprising the nanoparticular formulations of the present invention, as well as their use as contrast medium.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: November 21, 2017
    Assignee: NANOPET PHARMA GMBH
    Inventor: Malte Bahner
  • Patent number: 9821078
    Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.
    Type: Grant
    Filed: February 27, 2016
    Date of Patent: November 21, 2017
    Assignees: SHIMADZU CORPORATION, KYOTO UNIVERSITY
    Inventors: Eiichi Ozeki, Shunsaku Kimura, Akira Makino
  • Patent number: 9821079
    Abstract: The invention provides a conjugate with fluorochrome moiety F coupled to a targeting moiety T. Moiety F is described by formula (I), and the targeting moiety T is characterized in that it has affinity to a tumor marker, such as an antibody or antibody fragment. The conjugate may be used for tumor diagnostics including photodetection of tumor nodules during resection surgery.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: November 21, 2017
    Assignee: SURGIMAB S.A.S.
    Inventors: Françoise Cailler, Bérénice Framery
  • Patent number: 9821080
    Abstract: Non-invasive method of monitoring by radioactivity bioscanning the distribution of a biological entity in a subject in vivo by administering to the subject a radioiodinated form of the biological entity. The radioiodinated form is prepared by contacting an aqueous suspension of the biological entity with a radioiodinated construct of the structure F-S-L where F comprises a radioiodinated tyrosine moiety, S is a spacer covalently linking F to L, and L is a lipid.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: November 21, 2017
    Inventors: Nikolai Vladimirovich Bovin, Stephen Henry, Elena Yurievna Korchagina, Igor Leonidovich Rodionov, Alexander Borisovich Tuzikov
  • Patent number: 9821081
    Abstract: Perfume-free malodor reducing compositions comprising a malodor binding polymer and a malodor counteractant are provided. In some embodiments, the composition comprises a malodor binding polymer and GLDA. Such compositions may be used to reduce malodor on inanimate surfaces or in the air.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: November 21, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Kristin Rhedrick Williams, Linda Magenis Girard, Ian Christopher Tholking
  • Patent number: 9821082
    Abstract: A scent dispersal device and a network for operating one or more scent dispersal devices are provided. The device can include electronics for operating a heater within the device to cause a scent cartridge within the device to disperse a scent into the surrounding environment. The device can include a top configured to turn the device on/off and control the type, strength and duration of a specific scent from a scent cartridge. The device can be equipped with sensors to identify the type of scent selected and the level of scent substance remaining in a scent cartridge. The device can be configured to interact with other scent devices via a local Wi-Fi network, where the tactile control of one device causes other devices to act in the same manner. The device or devices can further be controlled by and send information to a mobile device via a network.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 21, 2017
    Assignee: The Yankee Candle Company, Inc.
    Inventors: Melanie Swartz, Ross Millenacker, Michael Li, Fan Sai Kuok, Vishal Pallikandi
  • Patent number: 9821083
    Abstract: A volatile substances evaporation device comprises a body (1) which can house an element (2) impregnated with volatile substances; an electric resistance (4); and a plug (5) for connection to a power grid; and said electrical resistance (4) is positioned in said plug (5) and said plug (5) is movable with respect to said body (1) so that the distance between the element (2) and said electrical resistance (4) is variable, defining at least one position of maximum evaporation and one position of minimum evaporation.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: November 21, 2017
    Assignee: ZOBELE ESPANA, S.A.
    Inventors: Jordi Maso Sabate, Cedric Gobber, Stefano Deflorian
  • Patent number: 9821084
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: November 21, 2017
    Assignee: Virginia Commonwealth University
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Patent number: 9821085
    Abstract: The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: November 21, 2017
    Assignee: DFine, Inc.
    Inventors: Csaba Truckai, Andrew Kohm, John Shadduck, Robert Luzzi
  • Patent number: 9821086
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: November 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
  • Patent number: 9821087
    Abstract: The disclosure relates to a bio-artificial periosteum based on micropatterning of biomimetic mineralized calcium-phosphorus nanoparticles and a method for manufacturing the same. The method includes: first, a micropatterned biomimetic mineralized calcium-phosphorus nanoparticle layer is manufactured on a surface of an inert substrate; then, an organic polymer is cross-linked and solidified on the micropatterned biomimetic mineralized calcium-phosphorus nanoparticle layer; at last, the inert substrate is removed, so that the bio-artificial periosteum based on micropatterning of biomimetic mineralized calcium-phosphorus nanoparticles is obtained. The bio-artificial periosteum not only simulates the composition of natural bone in material components, but also realizes high degree of biomimesis in micro-nano size in structure.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: November 21, 2017
    Assignee: HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Shengmin Zhang, Gaojie Yang, Haoming Liu, Yu Liu
  • Patent number: 9821088
    Abstract: Ionically cross-linked compositions containing carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are provided. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are also provided. Such compositions can be used by placing then in proximity to a tissue in need of lubrication or for prevention of adhesions and adhesion reformation.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 21, 2017
    Assignee: FZIOMED, Inc.
    Inventor: Samuel J. Falcone
  • Patent number: 9821089
    Abstract: Isolated composites are disclosed comprising collagen fibers isolated from a Sarcophyton sp. coral. An exemplary composite comprises as a first component a bundle of collagen fibers, the collagen fibers being isolated from a Sarcophyton sp. coral, and a second component selected from the group consisting of a polysaccharide, a polypeptide, polylipid, a synthetic polymer, a metal and a mineral, wherein the bundle of collagen fibers comprise woven fibers, twisted fibers, braided fibers, knitted fibers, tied fibers, or sutured fibers. Uses thereof and method of generating are also disclosed.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: November 21, 2017
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Rami Haj-Ali, Yehuda Benayahu, Dafna Benayahu, Aviad Sason-Levi, Mirit Sharabi
  • Patent number: 9821090
    Abstract: The present disclosure relates generally to coating medical devices. In particular, the present disclosure provides materials and methods for coating a portion of a balloon catheter with a pharmaceutical agent using electrodeposition techniques. Although angioplasty and stenting can be effective methods for treating vascular occlusions, restenosis remains a pervasiveness problem. Therefore, coating portions of a balloon catheter with a pharmaceutical agent that inhibits restenosis can reduce the likelihood of restenosis.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: November 21, 2017
    Assignee: The Spectranetics Corporation
    Inventor: Thomas Kelby Triffo
  • Patent number: 9821091
    Abstract: The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix. The methods relate to the application of pressure, and optionally, in combination with heat, to a polymeric coating.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: November 21, 2017
    Assignee: Abbot Cardiovascular Systems Inc.
    Inventors: Syed F. A. Hossainy, Fuh-Wei Tang, Lothar W. Kleiner, Thierry Glauser, Yiwen Tang, Wouter E. Roorda, Stephen D. Pacetti, Gina Zhang, Yung-Ming Chen, Andrew F. McNiven, Sean A. McNiven, Brandon J. Yoe
  • Patent number: 9821092
    Abstract: A protective coating solution, liquid, gel, or film and a method of using such a material to provide a sterile covering for fingers, hands, arms or other selected skin surface for use as a glove substitute.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: November 21, 2017
    Inventor: Bradley P. Bengtson
  • Patent number: 9821093
    Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: November 21, 2017
    Assignee: OrbusNeich Medical, Inc.
    Inventors: Robert John Cottone, Jr., Stephen M. Rowland, Sherry Parker
  • Patent number: 9821094
    Abstract: Antimicrobial metal ion coatings. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, niobium or rhenium) on a substrate so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 21, 2017
    Assignee: Silver Bullet Therapeutics, Inc.
    Inventors: Houdin Dehnad, Paul E. Chirico, Bohdan Wolodymyr Chopko, John Barr, Robert Vincent McCormick, Julie Lucero, Jason A. Jegge
  • Patent number: 9821095
    Abstract: One aspect of the invention is a method to vent gas from a body cavity during an endoscopic procedure. A body cavity is in fluid communication with an exhaust gas inlet of a vacuum break device. The vacuum break device has a chamber in fluid communication with both the inlet and an outlet. The chamber may comprise one or more openings in fluid communication with the atmosphere. A conduit in fluid communication with the exhaust gas outlet may be connected directly or indirectly to a suction source. The suction source may be activated.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: November 21, 2017
    Assignee: Lexion Medical, LLC
    Inventors: Duane Earl Lloyd, Keith A. Roberts
  • Patent number: 9821096
    Abstract: Tissue sampling, processing and injection syringe device and methods of filtering and concentrating cellular components of tissue sample in situ within the device.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 21, 2017
    Assignee: Rocin Laboratories, Inc.
    Inventor: Robert L. Cucin
  • Patent number: 9821097
    Abstract: A body cavity drainage device includes a drainage tube with a distal end configured for insertion into the body cavity of a patient, a fluid outlet at a proximal end of the drainage tube; and an activation apparatus coupled to the drainage tube between the proximal end of the drainage tube and the distal end of the drainage tube. The activation apparatus may be configured to alter a position of the distal end of the drainage tube in response to an input at a control device of the activation apparatus, and a first portion of the drainage tube extending from the activation apparatus toward the distal end may be at least substantially coaxial with a second portion of the drainage tube extending from the activation apparatus toward the proximal end. Methods relate to forming a body cavity drainage devices.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: November 21, 2017
    Assignee: Merit Medical Systems, Inc.
    Inventor: Harrison M. Lazarus
  • Patent number: 9821098
    Abstract: A method is provided of controlling a pump including a electrical motor coupled to a rotor which carries first and second impellers at opposite ends thereof. The method includes: (a) driving the rotor using the motor, so as to circulate fluid from the first impeller through a first fluid circuit, the second impeller, a second fluid circuit, and back to the first impeller; (b) determining a resistance of the first fluid circuit, based on a first motor parameter which is a function of electrical power delivered to the motor; (c) determining a flow rate through the first fluid circuit based on a second motor parameter which is a function of electrical power delivered to the motor; and (d) varying at least one operational parameter of the pump so as to maintain a predetermined relationship between the flow rate and the resistance of the first fluid circuit.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: November 21, 2017
    Assignee: CLEVELAND CLINIC FOUNDATION
    Inventors: David Horvath, Alex Massiello, Leonard A. R. Golding, Barry Kuban
  • Patent number: 9821099
    Abstract: An artificial-blood-vessel connector includes: a connector portion which includes a first cylindrical body portion where a male threaded portion and a flat surface portion where the male threaded portion is not formed are alternately formed along a circumferential direction of an outer peripheral surface, and a second cylindrical body portion to be fitted inside an artificial blood vessel; a ferrule which includes a cylindrical portion to be fitted on an outer peripheral surface of the second cylindrical body portion by way of the artificial blood vessel by being made to slide linearly on a surface of the artificial blood vessel, and a pawl plate portion in contact with the flat surface portion of the first cylindrical body portion; and a nut threadedly engageable with the male threaded portion of the first cylindrical body portion in a state where the nut covers the ferrule.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 21, 2017
    Assignee: SUN MEDICAL TECHNOLOGY RESEARCH CORPORATION
    Inventor: Takayuki Miyakoshi
  • Patent number: 9821100
    Abstract: Blood pump assemblies and methods of manufacturing and operating blood pump assemblies are provided. The blood pump assembly includes a pump and an impeller blade rotatably coupled to the pump. The blood pump assembly also includes a pump housing component sized for passage through a body lumen and coupled to the pump. The pump housing component includes a peripheral wall extending about a rotation axis of the impeller blade. The peripheral wall includes an inner peripheral wall surface and an outer peripheral wall surface. The peripheral wall also includes one or more blood exhaust apertures. Each blood exhaust aperture in the one or more blood exhaust apertures is defined by an inner aperture edge and an outer aperture edge. Each inner aperture edge is chamfered between the inner peripheral wall surface and the outer peripheral wall surface.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 21, 2017
    Assignee: Abiomed, Inc.
    Inventors: Scott C. Corbett, Zhongwei Qi, Kar Lee
  • Patent number: 9821101
    Abstract: A system and method for implanting a ventricular assist device (“VAD”) within the heart includes one or more tools, each having a body with a passage. Each tool body can be engaged with an anchor ring assembly secured to the heart. A coring tool can be advanced through the passage in a tool body and used to from a hole in the heart wall, and then valve actuating elements carried on the tool can be used to close a valve incorporated in the anchor ring assembly. A VAD can be passed into the heart through a passage in a tool body after opening the valve. The procedure can be performed while the heart continues to beat, without gross blood loss.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: November 21, 2017
    Assignee: HeartWare, Inc.
    Inventor: Lance Lynn Andrus
  • Patent number: 9821102
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 21, 2017
    Assignee: Gambro Lundia AB
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Patent number: 9821103
    Abstract: The present invention generally relates to systems and methods for the regeneration of spent dialysis solutions. The present invention further relates to systems and methods for continuously regenerating spent dialysis solution during dialysis. The present invention further relates to systems and methods for conducting dialysis that further include using chemical and physical separators in conjunction with ion exchange cartridges and/or adsorption cartridges.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: November 21, 2017
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventor: Harold F. Sandford
  • Patent number: 9821104
    Abstract: An extracorporeal blood treatment device for operation with a single patient connection, connected by an arterial and a venous blood line to an extracorporeal blood circuit, and a method for operating a blood treatment device with a single patient connection. The blood treatment device has two apparatuses for conveying blood in the arterial and venous blood lines. The second apparatus for conveying blood comprises means for collecting blood and means for establishing a pressure in the means for collecting blood, so that blood collected in the means for collecting blood flows to the patient connection. Furthermore, the blood treatment device has arterial and venous closure elements for interrupting the flow of liquid in the arterial and venous blood lines, as well as a control unit for actuating the two apparatuses for conveying blood and the arterial and venous closure elements.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 21, 2017
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Christoph Bocklet
  • Patent number: 9821105
    Abstract: Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. The nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The montmorillonite, the bentonite, and the other clays may be used in wearable systems, such as a wearable peritoneal dialysis system, in which a dialysis fluid is circulated through a filter with the nanoclay sorbents. Waste products are absorbed by the montmorillonite, the bentonite, and the other clays and the dialysis fluid is recycled to a patient's peritoneum. Using an ion-exchange capability of the montmorillonite, the bentonite, and the other clays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: November 21, 2017
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Rosa H. Yeh, Wei Xie, Hsinjin E. Yang, Michael T. K. Ling, Ying-Cheng Lo
  • Patent number: 9821106
    Abstract: An apparatus is described for extracorporeal blood treatment, comprising a treatment unit, an extracorporeal blood circuit and a fluid evacuation line. The apparatus comprises a control unit connected to a pressure sensor and configured to move a blood pump, generating a variable flow with a constant component equal to a desired blood flow value and a variable component having a nil mean value; the variable flow generates, in the expansion chamber, a pressure progression that is variable over time with a pressure component oscillating about a mean value. The control unit receives a plurality of values over a period of time comprising a plurality of oscillations of the pressure about the mean value, calculates a control value representative of the oscillating pressure component, and then determines the verification or not of a condition of variation of the blood level in the expansion chamber.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: November 21, 2017
    Assignee: Gambro Lundia AB
    Inventors: Alessandro Vasta, Francesco Fontanazzi, Mauro Suffritti